This article was originally published in The Gray Sheet
Shareholder InCentive Capital no longer intends to pursue an unsolicited takeover bid for the firm, Sulzer announces April 26. InCentive made a $2.6 bil. bid for Sulzer in February with the intention of accelerating a spinout of the firm's high-growth Sulzer Medica unit (1"The Gray Sheet" Feb. 26, 2001, p. 10). Sulzer has since proposed its own plan for spinning off the Medica business, a transaction that is expected take place in the third quarter
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.